Desvenlafaxine

CHEMBL1118 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
263.4 g/mol
LogP
2.6
Phase
4

An SNRI antidepressant and active metabolite of venlafaxine that inhibits the reuptake of both serotonin and norepinephrine, used for major depressive disorder and also investigated for vasomotor symptoms of menopause. It has a simpler metabolism than venlafaxine due to minimal CYP2D6 involvement.

น้ำหนักโมเลกุล

263.3700 g/mol

LogP

2.60

TPSA

43.70 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

กลไกการออกฤทธิ์

Inhibits the reuptake of both serotonin and norepinephrine by blocking their respective presynaptic transporters. This dual mechanism enhances monoaminergic neurotransmission and produces antidepressant and analgesic effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Inhibits the reuptake of both serotonin and norepinephrine by blocking their respective presynaptic transporters. This dual mechanism enhances monoaminergic neurotransmission and produces antidepressant and analgesic effects.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1

InChI

InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3

Molecular Formula

C16H25NO2

HBD / HBA

2 / 3

พันธะที่หมุนได้

4

อะตอมหนัก

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

An SNRI antidepressant and active metabolite of venlafaxine that inhibits the reuptake of both serotonin and norepinephrine, used for major depressive disorder and also investigated for vasomotor symptoms of menopause. It has a simpler metabolism than venlafaxine due to minimal CYP2D6 involvement.

Inhibits the reuptake of both serotonin and norepinephrine by blocking their respective presynaptic transporters. This dual mechanism enhances monoaminergic neurotransmission and produces antidepressant and analgesic effects.

Yes, Desvenlafaxine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1118. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 125017. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.